AMTD completes the HK IPO of IVD Medical

On July 12th, 2019, IVD Medical Holding Limited ("IVD Medical", Stock Code: 1931.HK), a leading distributor in the fast-growing PRC IVD market, is successfully listed on the Main Board of the Hong Kong Stock Exchange. AMTD is the Joint Bookrunner and Joint Lead Manager of IVD Medical's IPO and helped the company successfully land in the international capital market. This transaction is the third leading medical service company’s IPO that AMTD completed after IntelliCentrics (6819.HK) and Aptorum Group (NASDAQ: APM), and it is also the 10th IPO issuance of AMTD in 2019.

IVD Medical Holding Limited (1931.HK), a leading distributor in the fast-growing PRC IVD market, is successfully listed on the Main Board of the Hong Kong Stock Exchange. AMTD Group is the Joint Bookrunner and Joint Lead Manager of IVD Medical's IPO

 

IVD Medical offered 333.4 million shares with issue price at HKD3.07 per share and gross proceeds of around US$ 131 million. The company is a distributor of IVD products in the PRC, with its Original Group being the third largest distributor in the Shanghai IVD market. Vastec, a subsidiary that IVD Medical acquired in January 2019, was the fourth largest tier 1 distributorin the PRC IVD market in 2018. In addition, Vastec has been the sole national distributor of Sysmex’ haemostasis products, which had a market share of approximately 37.9% by revenue in 2018 in the PRC, representing the largest market share among all tier 1 distributors in the PRC haemostasis products market. IVD Medical also engage in the research, development, manufacturing and sales of its self-branded IVD products.

Mr. Ho Kuk Sing, Chairman, Executive Director and CEO of IVD Medical (2nd left), Mr. Leung King Sun, Chief Operation Officer of IVD Medical (2nd right) and Marcellus Wong, Vice Chairman of AMTD (1st right) and Neil Wang, Chief Strategic Alliance Officer of AMTD (1st left) attended the listing ceremony

 

AMTD has long term commitment to the medical sector. Prior to IVD Medical’s IPO, AMTD successfully assisted IntelliCentrics (6819.HK), a leading medical technology platform, listing on the Main Board of Hong Kong Stock Exchange this year, and Aptorum Group (NASDAQ: APM), a leading Hong Kong-based medical innovation and biopharmaceutical company, listing on the NASDAQ Stock Exchange in 2018.

As a comprehensive financial institution rooted in Hong Kong, based in the Greater Bay Area, backed by China and covering the globe, AMTD has always been committed to providing clients with open-end, innovative, diversified and professional financial services and helping more and more companies from different regions and diversified industries to expand business coverage, implement strategic goals and achieve global layout. In addition to medical sector, AMTD has also completed a number of Hong Kong and US IPOs for various industry-leading companies this year, including Impro (1286.HK), a global top 10 manufacturer of high-precision, high-complexity and mission-critical casting and machined components for diverse end-markets; Duiba (1860.HK), a China’s leading user management SaaS provider for online businesses and interactive advertising platform operator; Koolearn (1797.HK), a leading online extracurricular education service provider in China; Up Fintech (NASDAQ: TIGR), a leading online brokerage firm focusing on global and Chinese market; Aoyuan Healthy Life (3662.HK), a renowned property management service and commercial operational service provider; Maoyan Entertainment (1896.HK), “the first Hong Kong-listed company in China's Internet entertainment service industry”; Weimob (2013.HK), “the first Hong Kong-listed new economy SaaS company”; Weigang (1845.HK), a leading comprehensive hazardous waste incineration turnkey solution provider.